CML Education
Chronic myeloid leukemia management has entered a new era with treatment-free remission, next-generation TKIs, and stamp-out approaches reshaping long-term care. Knowledge Med sessions help physicians navigate TKI selection, molecular monitoring, and discontinuation decisions through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing chronic myeloid leukemia face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting first-line TKI therapy (imatinib, dasatinib, nilotinib, bosutinib) based on risk and comorbidities
- Interpreting molecular milestones and switching therapy for suboptimal response
- Identifying candidates for treatment-free remission and managing discontinuation
- Integrating asciminib and other novel agents for resistant disease
What Sessions Cover
Knowledge Med CML sessions use interactive case simulations to address these topics and more.
- Risk-adapted first-line TKI selection in chronic-phase CML
- Molecular monitoring milestones and therapy switching decisions
- Treatment-free remission: eligibility criteria, monitoring, and patient counseling
- Asciminib and emerging agents for resistant or intolerant CML
Interactive CML Sessions
Case Simulations
Work through realistic chronic myeloid leukemia patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key CML clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a CML Session
Third-party, non-promotional chronic myeloid leukemia education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session